Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment

globenewswire.com
ABBV AbbVie is mentioned as a major pharmaceutical company competing in the neuroprotective agents market, which is projected to grow significantly. The article does not provide specific sentiment towards AbbVie's performance or pipeline. AZN AstraZeneca is listed as a major pharmaceutical competitor in the growing neuroprotective agents market. The article does not offer specific details on their involvement or prospects within this segment. BIIB Biogen is named as a major pharmaceutical company in the competitive neuroprotective agents market. The article does not offer specific sentiment or details about Biogen's role or success in this area. BMY Bristol-Myers Squibb is listed among major pharmaceutical companies competing in the expanding neuroprotective agents market. No specific sentiment or performance data is provided for the company. GSK GSK is mentioned as a significant pharmaceutical competitor in the neuroprotective agents market. The article does not provide specific sentiment or details regarding GSK's pipeline or market position. LLY Eli Lilly is identified as a major pharmaceutical company competing in the growing neuroprotective agents market. The article does not offer specific sentiment or performance details for Lilly. MRK Merck & Co. is listed as a major pharmaceutical competitor in the neuroprotective agents market, which is expected to grow significantly. The article does not provide specific sentiment towards Merck. NVS Novartis is named as a key pharmaceutical company competing in the neuroprotective agents market. The article does not provide specific sentiment or details about Novartis's performance or pipeline. SNY Sanofi is mentioned as a major pharmaceutical competitor in the neuroprotective agents market, which is experiencing robust growth. The article does not provide specific sentiment or performance data for Sanofi. TEVA Teva Pharmaceutical Industries is listed as a major competitor in the neuroprotective agents market. The article does not provide specific sentiment or performance details for Teva. UCB UCB is identified as a major pharmaceutical company competing in the growing neuroprotective agents market. The article does not offer specific sentiment or details regarding UCB's pipeline or market position.

Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment Boston, March 26, 2026 (GLOBE NEWSWIRE) -- The global market for neuroprotective agents was valued at $41.2 billion in 2024 and is expected to reach $60.9 billion by the end of 2030, according to a new report from BCC Research. The market is projected to grow at a compound annual growth rate (CAGR) of 6.7% from 2025 through 2030.

Neuroprotective agents — therapeutics designed to prevent or slow neuronal damage and degeneration — represent one of the largest and most active segments in pharmaceutical development. The growing global burden of neurological diseases, including Alzheimer's disease, Parkinson's disease, stroke and multiple sclerosis, is driving sustained investment in both established and emerging therapeutic approaches.

Key Market Findings

Market Drivers

The surge in neurological disorders globally is the fundamental growth driver. The World Health Organization estimates that neurological conditions affect hundreds of millions of people worldwide, with prevalence rising as populations age. The rising prevalence of neurological conditions among the elderly is compounding demand, while growing awareness of neuroprotective therapeutic options is expanding the treatable patient population.

Rising healthcare investments and strategic focus from pharmaceutical and biotech companies on neuroscience pipelines are accelerating the development of next-generation therapies.

Technology and Competitive Landscape

Emerging technologies transforming the field include precision medicine approaches for neurological disorders, gene therapy for neurodegenerative conditions, neurodegeneration-targeted stem cell therapies, and nanotechnology-based drug delivery systems that improve blood-brain barrier penetration.

The market features intense competition among major pharmaceutical companies including AbbVie, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, F. Hoffmann-La Roche, GSK, Lilly, Merck & Co., Novartis, Sanofi, Teva Pharmaceutical Industries and UCB. A growing cohort of emerging startups is also entering the space with novel therapeutic approaches.

Investment Considerations

Key risks include the historically high failure rate of clinical trials in the neuroprotective product line and the substantial cost of drug development in neuroscience. The complexity of CNS drug targets and the challenges of demonstrating neuroprotective efficacy in clinical settings remain significant barriers. However, recent regulatory approvals — particularly in Alzheimer's disease — have reinvigorated investor confidence and pipeline activity.

About the Report

Neuroprotective Agents: Therapeutic Applications and Global Markets (Report Code: PHM188B) provides comprehensive market analysis including pipeline assessment, patent analysis, segmentation by indication, therapy type, drug class and region, along with detailed competitive intelligence. The report is available now from BCC Research.

→ Download the Free Report Overview

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Any data extracted from this release must be accompanied by a statement identifying BCC Research LLC as the source.